Skip to Content
Merck
CN

SML2955

Sigma-Aldrich

Mirodenafil dihydrochloride

≥98% (HPLC)

Synonym(s):

4-[[3-(5-Ethyl-4,5-dihydro-4-oxo-7-propyl-1H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenyl]sulfonyl]-1-piperazineethanol, dihydrochloride, 5-Ethyl-2-[5-[[4-(2-hydroxyethyl)piperazin-1-yl]sulfonyl]-2-propoxyphenyl]-7-propyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one, dihydrochloride, 5-Ethyl-3,5-dihydro-2-[5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]-2-propoxyphenyl]-7-propyl-4H-pyrrolo[3,2-d]pyrimidin-4-one, dihydrochloride, SK 3530 dihydrochloride, SK-3530 dihydrochloride, SK3530 dihydrochloride

Sign Into View Organizational & Contract Pricing

Select a Size

About This Item

Empirical Formula (Hill Notation):
C26H37N5O5S·2HCl
CAS Number:
862189-96-6
Molecular Weight:
604.59
MDL number:
MFCD28139019
UNSPSC Code:
12352200
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

[S](=O)(=O)(N4CCN(CC4)CCO)c1cc(c(cc1)OCCC)c2[nH][c](c3[n](cc(c3n2)CCC)CC)=O.Cl.Cl

InChI

1S/C26H37N5O5S.2ClH/c1-4-7-19-18-30(6-3)24-23(19)27-25(28-26(24)33)21-17-20(8-9-22(21)36-16-5-2)37(34,35)31-12-10-29(11-13-31)14-15-32;;/h8-9,17-18,32H,4-7,10-16H2,1-3H3,(H,27,28,33);2*1H

InChI key

CKPHITUXXABKDL-UHFFFAOYSA-N

Related Categories

Biochem/physiol Actions

Mirodenafil (SK3530) is an orally active, highly potent and selective phosphodiesterase-5 (PDE5) inhibitor (IC50 = 338 pM). with therapeutic efficacy in various ED models in vivo. Comparing to sildenafil, mirodenafil shows ~10-times higher PDE5 selectivity in vitro and remains longer in the plasma and corpus cavernosum following oral dosing at 40 mg/kg in rats in vivo.
Orally active, highly potent and selective phosphodiesterase-5 (PDE5) inhibitor with ED therapeutic efficacy in vivo.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000119244
0000119448
0000106108

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jung Yoon Kang et al.
Korean journal of urology, 54(5), 339-344 (2013-05-24)
We investigated the effects of mirodenafil, a phosphodiesterase-5 inhibitor developed in South Korea, on the female rat bladder in a partial bladder outlet obstruction (BOO) model. Thirty-six female Sprague-Dawley rats were divided into four groups: the control group, BOO without
Kwanjin Park et al.
European urology, 53(6), 1282-1288 (2008-02-05)
To examine whether chronic treatment with a type 5 phosphodiesterase inhibitor (PDE5I) could suppress corporal apoptosis via potentiation of Akt signalling in diabetic erectile dysfunction. Sprague-Dawley rats (12 wk old) were divided into three groups (n=12 in each): normal control
Jung Jun Kim et al.
Asian journal of andrology, 13(5), 742-746 (2011-04-12)
In this study, we investigated the effects of a combination of Ginkgo biloba extracts (GBE) and phosphodiesterase type 5 (PDE-5) inhibitors on the muscular tone of the corpus cavernosum and potassium channel activity of corporal smooth muscle cells. Strips of
Hoon Choi et al.
International neurourology journal, 19(1), 19-26 (2015-04-04)
To investigate the protective effect of mirodenafil on bladder function in a rat model of chronic bladder ischemia (CBI). Twenty-four Sprague-Dawley rats were randomized to three groups: untreated, sham-operated rats (control group); untreated, CBI model rats (CBI group); and CBI
H Kim et al.
International journal of impotence research, 22(5), 291-297 (2010-09-24)
Impotence is one of the common complications after the radical prostatectomy. One of the main reasons of this complication is due to the dysfunction of the veins in corpus cavernosum. Recent studies have shown that the erectile function is improved
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service